Literature DB >> 19437423

Mass spectrometric characterisation and quantitation of selected low molecular mass compounds from the venom of Haplopelma lividum (Theraphosidae).

Sara Moore1, W Franklin Smyth, Victor A Gault, Edmund O'Kane, Stephen McClean.   

Abstract

Arachnid venoms present a diverse and complex matrix for investigation, with their latent potential for innovative drug and pesticide design largely unrealised. The characterisation and quantification of selected low molecular mass compounds isolated from the crude venom of the Cobalt blue tarantula (Haplopelma lividum) were the objectives of this study. Fractionation of the crude venom was performed using reversed-phase high-performance liquid chromatography, with compound identification using both electrospray ionisation ion trap mass spectrometry and quadrupole time-of-flight mass spectrometry. Four compounds were identified, and quantification on a percentage dry weight basis was achieved by liquid chromatography/electrospray ionisation tandem mass spectrometry based on the formation of their corresponding product ions. Of these the most abundant component was glutamic acid, present at a level of 0.97%. Histamine and adenosine were detected at 0.14% and 0.10% dry weight, respectively, with the polyamine spermine noted in trace amounts at 0.002%. The limits of detection and quantification were established for each of the identified components. The fragmentation profile for histamine has also been proposed. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437423     DOI: 10.1002/rcm.4063

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  1 in total

1.  A Novel Toxin from Haplopelma lividum Selectively Inhibits the NaV1.8 Channel and Possesses Potent Analgesic Efficacy.

Authors:  Ping Meng; Honggang Huang; Gan Wang; Shilong Yang; Qiuming Lu; Jingze Liu; Ren Lai; Mingqiang Rong
Journal:  Toxins (Basel)       Date:  2016-12-26       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.